Megestrol Acetate as a Treatment for Anorexia in Hemodialysis Patients

Authors

  • José L. Teruel Nephrology Department, Hospital Ramón y Cajal, Madrid, Spain
  • Milagros Fernández-Lucas Nephrology Department, Hospital Ramón y Cajal, Madrid, Spain
  • Roberto Marcén Nephrology Department, Hospital Ramón y Cajal, Madrid, Spain
  • Antonio Gomis Nephrology Department, Hospital Ramón y Cajal, Madrid, Spain
  • Sandra Elías Nephrology Department, Hospital Ramón y Cajal, Madrid, Spain
  • Viviana Raoch Nephrology Department, Hospital Ramón y Cajal, Madrid, Spain
  • Carlos Quereda Nephrology Department, Hospital Ramón y Cajal, Madrid, Spain

DOI:

https://doi.org/10.6000/1929-5634.2014.03.02.3

Keywords:

Anorexia, Hemodialysis, Malnutrition, Megestrol acetate

Abstract

Background: The aim of this study was to evaluate the effectiveness of megestrol acetate as a treatment for anorexia in hemodialysis patients.

Materials and Methods: From 1st January 2008 to 31st December 2010, 29 patients in our Hemodialysis Unit were treated with megestrol acetate (initial dose: 160 mg / day) for anorexia associated with a decrease in dry body weight. Sixteen patients had a protein-energy wasting syndrome.

Results: Appetite improved in 25 patients, but the initial dose of megestrol acetate had to be increased in 8 patients. At three months, there was an increase in dry body weight (63.4 vs 61.9 kg, p=0.002), serum albumin level (3.98 vs 3.77 g/dl, p<0.001), serum creatinine level (10.5 vs 9.6 mg/dl, p=0.016) and protein catabolic rate (1.21 vs 0.98 g / kg / day, p < 0.001). The response was independent of the cause of anorexia. A bioelectrical impedance analysis, carried out in 9 patients, showed that treatment with megestrol acetate increased the body cell mass and changed the distribution of body water by increasing intracellular water. The megestrol acetate treatment was well-tolerated and no patients left the study due to side effects or adverse reactions.

Conclusions: Megestrol acetate improves appetite and nutritional parameters in anorexic patients treated with maintenance hemodialysis.

References

Burrowes JD, Larive B, Chertow GM, Cockram DB, Dwyer JT, Greene T, Kusek JW, Leung J, Rocco MV for the HEMO Study Group: Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the Hemodialysis (HEMO) Study. Nephrol Dial Transplant 2005: 20: 2765-2774. http://dx.doi.org/10.1093/ndt/gfi132 DOI: https://doi.org/10.1093/ndt/gfi132

Lopes AA, Elder SJ, Ginsberg N, et al. Lack of appetite in haemodialysis patients - associations with patients characteristics, indicators of nutritional status and outcomes in the international DOPPS. Nephrol Dial Transplant 2007; 22: 3538-3546. http://dx.doi.org/10.1093/ndt/gfm453 DOI: https://doi.org/10.1093/ndt/gfm453

Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80: 299-307. DOI: https://doi.org/10.1093/ajcn/80.2.299

López AP, Figuls MR, Cuchi GU, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. Pain Symptom Manage 2004; 27: 360-369. http://dx.doi.org/10.1016/j.jpainsymman.2003.09.007 DOI: https://doi.org/10.1016/j.jpainsymman.2003.09.007

Lien YH, Ruffenach SJ. Low dose megestrol increases serum albumin in malnourished dialysis patients. Int J Artif Organs 1996; 19: 147-150. DOI: https://doi.org/10.1177/039139889601900302

Williams JL, Perius M, Humble A, Sigler D, Urbanes A, Shapiro HS. Effects of megestrol acetate on nutritional status of malnourished hemodialysis patients. J Ren Nutr 1997: 7: 231 [Abstract] http://dx.doi.org/10.1016/S1051-2276(97)90035-2 DOI: https://doi.org/10.1016/S1051-2276(97)90035-2

Burrowes JD, Bluestone PA, Wang J, Pierson RN. The effects of moderate doses of megestrol on nutritional status and body composition in a hemodialysis patient. J Ren Nutr 1999; 9: 89-94. http://dx.doi.org/10.1016/S1051-2276(99)90006-7 DOI: https://doi.org/10.1016/S1051-2276(99)90006-7

Boccanfuso JA, Hutton M, McAllister B. The effects of megestrol acetate on nutritional parameters in a dialysis population. J Ren Nutr 2000; 10: 36-43. http://dx.doi.org/10.1016/S1051-2276(00)90021-9 DOI: https://doi.org/10.1016/S1051-2276(00)90021-9

Costero O, Bajo MA, del Peso G, et al. Treatment of anorexia and malnutrition in peritoneal dialysis patients with megestrol acetate. Adv Perit Dial 2004; 20: 209-212.

Rammohan M, Kalantar-Zadeh K, Liang A, Ghossein C. Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. J Ren Nutr 2005; 15: 345-355. http://dx.doi.org/10.1016/j.jrn.2004.10.006 DOI: https://doi.org/10.1016/j.jrn.2004.10.006

Golebiewska J, Lichodziejewska-Niemierko M, Aleksandrowicz E, Majkowicz M, Lysiak-Szydlowska W, Rutkowski E. Influence of megestrol acetate on nutrition and inflammation in dialysis patients – preliminary results. Acta Biochim Pol 2009; 56: 733-737. [12] Monfared A, Heidarzadeh A, Ghaffari M, Akbarpour M. Effect of megestrol acetate on serum albumin level in malnourished dialysis patients. J Ren Nutr 2009; 19: 167-171. http://dx.doi.org/10.1053/j.jrn.2008.11.003 DOI: https://doi.org/10.18388/abp.2009_2510

Yeh SS, Marandi M, Thode HC, et al. Report of a pilot, doubleblind, placebo-controlled study of megestrol acetate in elderly dialysis patients with caquexia. J Ren Nutr 2010; 20: 52-62. http://dx.doi.org/10.1053/j.jrn.2009.08.005 DOI: https://doi.org/10.1053/j.jrn.2009.08.005

Fernández Lucas M, Teruel JL, Burguera V, et al. Tratamiento de la anorexía urémica con acetato de megestrol. Nefrología 2010; 30: 646-652.

Burrowes JD, Larive B, Cockram DB, et al. Effects of dietary intake, appetite, and eating habits on dialysis and non-dialysis treatment days in hemodialysis patients: cross-sectional results from the HEMO study. J Ren Nutr 2003; 13: 191-198. http://dx.doi.org/10.1016/S1051-2276(03)00069-4 DOI: https://doi.org/10.1016/S1051-2276(03)00069-4

Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73: 391-398. http://dx.doi.org/10.1038/sj.ki.5002585 DOI: https://doi.org/10.1038/sj.ki.5002585

Sargent JA. Control of dialysis by a single-pool urea model: The National Cooperative Dialysis Study. Kidney Int Suppl 1983; 13: S19-S25.

Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 1995; 122: 843-845. http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00006 DOI: https://doi.org/10.7326/0003-4819-122-11-199506010-00006

Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M. Glucocorticoid activity of megestrol. A Summary of Food and Drug Administration Experience and a Review of the Literature. Arch Intern Med 1997; 157: 1651-1656. http://dx.doi.org/10.1001/archinte.1997.00440360053005 DOI: https://doi.org/10.1001/archinte.1997.00440360053005

Downloads

Published

2014-06-16

How to Cite

Teruel, J. L., Fernández-Lucas, M., Marcén, R., Gomis, A., Elías, S., Raoch, V., & Quereda, C. (2014). Megestrol Acetate as a Treatment for Anorexia in Hemodialysis Patients. Journal of Nutritional Therapeutics, 3(2), 50–54. https://doi.org/10.6000/1929-5634.2014.03.02.3

Issue

Section

Articles